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Abstract 
Purpose: To report expanded SD-OCT findings of HCQ retinopathy that may assist the clinician in earlier diagnosis. To 
characterize structural changes of HCQ retinopathy with SD-OCT after drug cessation.
Methods: Setting: Private practice and academic institution. Patient Population: Patients at New England Eye Center 
and Ophthalmic Consultants of Boston in Boston, MA diagnosed with HCQ retinopathy and followed after drug ces-
sation. Retrospective clinical data review by the Boston Image Reading Center. Main Outcome Measures: SD-OCT find-
ings suggestive of HCQ retinopathy before parafoveal ellipsoid disruption. Change in SD-OCT morphological appear-
ance and retinal thickness of each of the nine subfields corresponding to the Early Treatment of Diabetic Retinopathy 
Study areas.
Results: Thirty eyes with HCQ retinopathy were followed with SD-OCT after drug cessation. Findings before dis-
ruption of the parafoveal EZ included parafoveal outer nuclear layer (ONL) thinning, disruption of the parafoveal 
interdigitation zone, and reduced reflectivity of the parafoveal EZ. In early toxicity, 75 % developed progression after 
drug cessation, including disruption of the parafoveal EZ and retinal pigment epithelium and thinning of the ONL. 
Eyes with obvious toxicity had greater inferior outer ring thinning 12 months after drug cessation compared to early 
toxicity (p = 0.002, 95 % CI −2 to −8 μm). In obvious toxicity, the nasal inner subfield showed more thinning than the 
temporal inner subfield at 12 months after drug cessation (p = 0.018, 95 % CI −1 to −8 μm).
Conclusions: Once HCQ retinopathy is diagnosed and the medication is discontinued, structural retinal changes 
commonly occur.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hydroxychloroquine (HCQ) has been used for therapy 
of rheumatologic disorders since the 1950s. Ocular tox-
icity associated with HCQ use was initially described in 
the 1960s [1, 2]. The incidence of HCQ retinopathy is 
estimated at 1 % after consumption of HCQ for 5 years 
[3]. It is marked by paracentral and central scotoma and 
decreased color vision. Risk factors predisposing to the 
development of HCQ retinopathy include a daily dose 
>6.5  mg/kg, cumulative dose >1000  g, duration of use 
over 5 years, elderly age, kidney or liver dysfunction, or 
preexisting maculopathy [4]. HCQ retinopathy is rare 
considering the widespread utilization of this drug; how-
ever, the retinopathy has potential to produce irreversible 
visual loss [1].
There is limited data regarding structural and functional 
changes of HCQ retinopathy after drug cessation [5–7]. 
Studies from the 1960s and 1970s evaluated individuals 
taking the more toxic, related drug chloroquine, but were 
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limited to visual acuity, visual fields, and fundus examina-
tion to assess for progression of retinopathy. In addition, 
these studies typically evaluated patients with advanced 
disease who had already developed a Bull’s eye fundus 
appearance. In the present day, the less toxic HCQ is used 
instead of chloroquine. The American Academy of Oph-
thalmology revised the screening guidelines in 2011 to 
include spectral domain-optical coherence tomography 
(SD-OCT), fundus autofluorescence (FAF), and multifo-
cal ERG (mfERG) when available to assess the macula in 
patients taking HCQ [4]. The new guidelines were designed 
for earlier detection of HCQ retinopathy before fundu-
scopic changes become apparent. Studies reviewing mfERG 
and FAF after drug cessation have demonstrated both pro-
gression and improvement in retinal function in moderate 
to severe toxicity [8–11]. It is unclear whether less severe 
cases of retinopathy progress after HCQ cessation.
SD-OCT is a highly sensitive and reproducible imaging 
modality commonly used in clinical practice. SD-OCT 
is capable of detecting characteristic macular changes 
of HCQ toxicity. These typical macular abnormalities 
include loss of the parafoveal ellipsoid zone (EZ), para-
foveal thinning of the outer nuclear layer (ONL) and 
inner plexiform layer (IPL), the “flying saucer” sign, and 
peripapillary nerve fiber layer thinning [12–14]. Few 
reports have examined progression of changes in SD-
OCT appearance after drug cessation. Marmor et al. [11] 
reported that SD-OCT appearance in patients with early 
HCQ toxicity, defined as patchy parafoveal visual field 
defects, did not change after drug cessation. However, 
moderate cases, defined as a 50–100  % parafoveal ring 
of damage on visual field testing, did demonstrate pro-
gressive parafoveal thinning. Kellner et  al. [15] showed 
long-term follow-up of eyes with moderate to severe 
chloroquine/HCQ toxicity resulting in cystoid macular 
edema and epiretinal membrane formation. However, no 
changes were observed in early toxicity.
This study examines longitudinal SD-OCT scans after 
cessation of HCQ and stratifies eyes based on severity 
of retinopathy to evaluate whether this plays a role in 
structural changes. An independent reading center was 
used to limit observational bias in interpreting the SD-
OCT scans. Furthermore, SD-OCT findings are identi-
fied before clear parafoveal ellipsoid zone (EZ) disruption 
becomes apparent, which may enable earlier diagnosis of 
HCQ retinopathy.
Methods
Data collection was obtained following approval from the 
Internal Review Board (IRB) of Tufts Medical Center, and 
was in compliance with the Health Insurance Portability 
and Accountability Act. Research tenets were followed in 
accordance with the Declaration of Helsinki.
A retrospective, consecutive case series of eyes with 
HCQ retinopathy that were followed after drug cessa-
tion was conducted at New England Eye Center, Boston, 
Massachusetts and Ophthalmic Consultants of Boston, 
Boston, Massachusetts. The study interval was from Jan-
uary 1, 2006 to July 12, 2013. Eyes were included if they 
were diagnosed with HCQ retinopathy and had SD-OCT 
imaging at the time of drug cessation and on follow-up 
exam. In addition, eyes were included only if the follow-
up SD-OCTs were performed on the same machine—
either Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) 
or Heidelberg Spectralis HRA + OCT (Heidelberg Engi-
neering, Germany).
HCQ retinopathy was diagnosed by detecting abnor-
malities attributable to HCQ on clinical examination, 
Humphrey 10-2 or 24-2 visual fields, SD-OCT, and/or 
FAF when available. Of note, all eyes in this study had 
visual field defects consistent with HCQ toxicity. Mul-
tifocal ERG was performed in only 8 eyes, and in these 
eyes, toxicity was confirmed with visual field defects and 
SD-OCT findings. Therefore, mfERG was not included in 
the analysis. Eyes were excluded if there was no clinical 
examination on record coincident with the time of HCQ 
cessation, if the follow up OCT was performed on a dif-
ferent OCT machine than at the time of drug cessation, 
or if time-domain OCT was performed. Ocular symp-
toms, best-available visual acuity, macular appearance, 
and imaging modalities (OCT, FAF) available at the time 
of HCQ retinopathy diagnosis and after HCQ cessation 
were recorded. The cumulative HCQ dose was calculated.
The first primary outcome measure was the morpho-
logical change in 1-line horizontal OCT scans from the 
time of discontinuing HCQ to the most recent examina-
tion. Vertical OCT scans were not routinely ordered by 
the treating physician and therefore unable to be included 
in analysis. If there were SD-OCT images available that 
demonstrated findings that preceded disruption of the 
parafoveal EZ, these findings were recorded and analyzed 
by the reading center. The second primary outcome meas-
ure was the change in retinal thickness in each of the 9 
Early Treatment of Diabetic Retinopathy Study (ETDRS) 
OCT sub-fields at 12 months after drug cessation.
The SD-OCT scans were evaluated by two masked, 
trained readers from the Boston Image Reading Center 
(BIRC, Boston, MA). The readers were provided raw data 
from the cube scans, which were qualitatively assessed 
for alterations in the normal morphological retinal fea-
tures. Readers analyzed SD-OCT images from the time 
of drug cessation and most recent follow up exam, and 
assessed whether any interval changes had occurred. 
After careful deliberation, common features which were 
most consistently recorded were decreased reflectivity of 
the ellipsoid zone (EZ), disruption of the EZ, disruption 
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of the interdigitation zone (IZ), disruption of the retinal 
pigment epithelium (RPE), disruption of the external lim-
iting membrane (ELM), and thinning of the outer nuclear 
layer (ONL). These characteristics were evaluated to 
be present or absent in both the foveal region (central 
1500  μm) and parafoveal region (0–2000  μm from the 
border of the foveal region on either side). The findings 
were considered true findings only if both readers agreed 
on the finding (i.e. hyporeflective, RPE atrophy, etc.) and 
the location of the finding (i.e. fovea, nasal parafovea, 
temporal parafovea, or both nasal and temporal para-
fovea). In no instances was there an opposite finding on 
either side of the fovea, such as hyperreflectivity on the 
nasal side and hyporeflectivity on the temporal side.
 For data analysis, the primary cohort was divided into 
three groups based on BIRC’s grading of the 1-line hori-
zontal OCT scan through the fovea at the time of drug 
cessation (Fig.  1). The purpose of the division was to 
separate early, obvious, and severe cases of toxicity, as 
the development of new screening modalities such as SD-
OCT has allowed for detection of earlier cases of HCQ 
toxicity. The Early group consisted of eyes presenting 
without clear disruption of both the foveal and parafoveal 
ellipsoid zone (EZ) as judged by BIRC’s interpretation of 
the SD-OCT at the time of drug cessation. Fundus exami-
nation of these eyes showed early macular findings, or 
none at all, at the time of diagnosis. The Obvious group 
consisted of eyes presenting with an intact foveal EZ but a 
clearly disrupted parafoveal EZ on either one or both sides 
of the fovea as judged by the BIRC graders. These eyes 
clinically manifested the classic parafoveal RPE changes. 
The Severe group consisted of eyes presenting with clear 
foveal EZ disruption with associated parafoveal EZ dis-
ruption. These eyes had poor visual acuity at presentation 
due to foveal and parafoveal outer retinal atrophy.
Retinal thickness measurements of each of the nine 
subfields corresponding to the Early Treatment of Dia-
betic Retinopathy Study (ETDRS) areas were examined. 
ETDRS SD-OCT thickness measurements consist of nine 
separate regions, which are defined by three concentric 
rings centered on the fovea with diameters of 1, 3, and 
6 mm, respectively. The two outer rings are divided into 
quadrants by two intersecting orthogonal lines. Only 
eyes that underwent SD-OCT imaging at baseline and 
follow-up with either Cirrus HD-OCT (Carl Zeiss Med-
itec, Dublin, CA) or Heidelberg Spectralis HRA + OCT 
(Heidelberg Engineering) were included in this analysis. 
Eyes that had baseline Stratus OCT (Carl Zeiss Meditec, 
Dublin, CA) were excluded.
Statistical analysis was performed using GraphPad 
(GraphPad Software, Inc., La Jolla, CA USA). We used an 
unpaired t test to compare the changes in retinal thick-
ness between the groups, while a paired t-test was used 
to compare the changes within a group. 95 % confidence 
intervals were calculated for any statistically significant 
changes observed as defined as p < 0.05.
Results
Thirty-six patients were identified with HCQ retinopathy. 
Thirteen patients were excluded because an OCT was 
not performed at the time of diagnosis. Eight patients 
were excluded for having a time domain-OCT at the time 
of drug cessation. Thirty eyes of 15 female patients met 
inclusion criteria and were followed by repeated exami-
nations after drug cessation. Clinical features of each 
patient are outlined in Table  1 and in each of the three 
groups in Table  2. All patients were Caucasian. Half of 
the eyes were emmetropic, and half were ametropic 
(range −6.0 to +6.0 diopters). None of the patients had 
kidney or liver dysfunction.
Fig. 1 Fundus photograph and SD-OCT example of each group. Cohort divided into three groups based on BIRC’s grading of ellipsoid zone at the 
time of drug cessation. Early—no disruption of parafoveal or foveal EZ; Obvious—disruption of parafoveal EZ with intact foveal EZ; Severe—disrup-
tion of both foveal and parafoveal EZ
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SD-OCT data was available for all 30 eyes at the time 
of drug cessation and follow up examinations. The Early 
group comprised of eight eyes of 5 patients. The Obvious 
group comprised of 17 eyes of 9 patients. The Severe group 
comprised of 5 eyes of three patients. The right eye of 
patient E2 qualified for the Early group and the left eye for 
the Severe group. The right eye of patient E3 qualified for 
the Obvious group and the left eye for the Early group. All 
qualitative observations had a strong inter-observer corre-
lation between the two observers from the reading center.
SD‑OCT at time of drug cessation
Morphological appearance of 1-line horizontal SD-OCT 
scans in each of the groups at the time of drug cessation 
is shown in Fig.  2. In the fovea, 25  % of the Early eyes 
and 59 % of the Obvious eyes had clear disruption of the 
interdigitation zone (IZ) in the absence of ellipsoid zone 
disruption, suggesting that IZ disruption may precede 
EZ disruption. By our definition of the three groups, no 
patients in the Early or Obvious group had foveal dis-
ruption of the EZ while all patients in the Severe group 
did. In the Severe group, foveal external limiting mem-
brane (ELM) disruption was observed in 40 %, while this 
Table 1 Clinical summary of patients
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Table 2 Baseline characteristics of each group
Median (range) reported for age, cumulative dose, and follow-up
Early Obvious Severe
Age (years) 63 (57–74) 65 (48–75) 74 (63–76)
Cumulative dose 
(g)
730 (438–949) 1933 (584–4380) 1030 (890–1679)
Baseline vision 20/20–20/40 20/20–20/60 20/100–20/400
Follow-up (months) 13 (12–56) 36 (12–56) 14 (13–36)
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finding was not present in the other two groups. Foveal 
retinal pigment epithelium (RPE) disruption was not 
observed at baseline in any group. Foveal thinning of the 
outer nuclear layer (ONL) was not present at baseline in 
any group.
In the parafoveal region, early SD-OCT findings were 
frequently detected in Early eyes in the absence of clear 
parafoveal EZ disruption (Fig.  3). Outer nuclear layer 
(ONL) thinning was present in 100 % and observed as a 
focal indentation in the parafoveal ONL when compared 
to peripheral ONL thickness. Disruption of the parafo-
veal interdigitation zone (IZ) was recorded in 88  % and 
reduced reflectivity of the parafoveal EZ band in the 
absence of definitive disruption was observed in 50  %. 
The reduced reflectivity of the parafoveal EZ enhanced 
the appearance of the foveal EZ, creating the illusion of 
increased prominence or hyperreflectivity of the foveal 
EZ (Fig. 4). Parafoveal RPE disruption was not detected 
in Early eyes, but was notable in 47  % of Obvious eyes 
and 40 % of Severe eyes. 
Progression of SD‑OCT changes after drug cessation
Morphological SD-OCT changes in each group after 
drug cessation is shown in Fig.  2. An interval change in 
SD-OCT appearance suggesting structural progression 
of toxicity was observed in 75 % Early, 71 % Obvious, and 
100 % of Severe eyes. In the Early group, 50 % developed 
clear parafoveal EZ disruption after drug cessation with 
a median follow-up of 13 months (range 12–77 months; 
Fig. 5). Increased parafoveal EZ disruption was observed 
in 60 % of the Obvious and Severe eyes. Increased parafo-
veal RPE disruption was detected in 13 % Early eyes, 47 % 
Obvious eyes, and 60 % Severe eyes. There was no signifi-
cant difference in the frequency or severity of temporal 
parafovea changes compared to the nasal parafovea. Fove-
ally, the most common change seen on SD-OCT after 
drug cessation was progressive ONL thinning in 25  % 
Early, 35  % Obvious, and 40  % Severe eyes. Progressive 
foveal RPE disruption was not detected. The latest time 
point in which progression was observed was progressive 
parafoveal RPE atrophy continuing for 4 years after drug 
Fig. 2 (Top row) reading center’s grading of SD-OCTs at time of HCQ discontinuation in fovea and parafovea. (Bottom row) reading center’s grading 
of interval changes in SD-OCT appearance of most recent follow-up exam compared to time of HCQ cessation. If thinning, disruption, or thicken-
ing was present at the time of drug cessation and an interval change was noted, the change was progressive or worsening thinning, disruption, or 
thickening
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cessation (Fig.  6). Finally, a reduction in disruption or 
improvement in SD-OCT appearance was not observed.
Macular thickness changes
Figure  7 illustrates the change between HCQ cessation 
and 12  months after cessation in each of the 9 ETDRS 
SD-OCT subfields. Decreases in central macular thick-
nesses were 3, 6, and 2  μm in the Early, Obvious, and 
Severe groups, respectively. The largest reduction in 
ETDRS map region thickness was 7 μm in the superior, 
nasal, and inferior outer rings of the Obvious group. 
When comparing thickness changes in the Obvious 
Fig. 3 SD-OCT findings of early toxicity preceding the development of parafoveal EZ disruption
Fig. 4 Examples of two Early patients. a E1, fundus photograph shows mild parafoveal RPE changes in each eye with unremarkable FAF. HVF 10-2 
shows incomplete parafoveal ring scotoma in right eye and parafoveal ring scotoma in left eye. SD-OCT of each eye shows no clear disruption of 
parafoveal EZ. However, reduced reflectivity of the parafoveal EZ (arrow) on both sides of the fovea is observed and enhances the appearance of the 
foveal EZ. Abrupt discontinuation of the parafoveal interdigitation zone (IZ) (arrowhead) is also observed on both sides of the fovea. b E4, Fundus 
autoflourescence is unremarkable. HVF 10-2 shows incomplete parafoveal ring scotomas in each eye. No clear disruption of the parafoveal EZ is 
seen on SD-OCT. However, the reflectivity of the parafoveal EZ is diminished (arrow) and enhances the appearance of the foveal EZ. There is also 
thinning of the parafoveal outer nuclear layer causing broadening of reflectivity of the parafoveal Henle’s fiber layer (arrowhead) on both sides of the 
fovea
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group to the Early group, a significant difference was 
found in the inferior outer ring (p = 0.002, 95 % CI −2 to 
−8 μm). No differences between the groups were found 
in the other subfields. When comparing different subfield 
thickness changes within an individual group, no differ-
ences were observed within the Early or Severe groups. 
However in the Obvious group, the nasal inner subfield 
showed more thinning than the temporal inner subfield 
(p = 0.018, 95 % CI −1 to −8 μm; Table 3). 
A subanalysis of eyes with at least 3 years of follow-up 
after drug cessation (N  =  11 eyes; patients E3, E5, O2, 
O3 OD, O4, O7; O3 OS excluded because of poor quality 
image at 42 month follow-up visit; S1 excluded because 
of widespread atrophy) was performed (Fig.  8). A pro-
gressive decline in retinal thickness beyond 1  year was 
observed in 62  % of eyes. Median subfoveal thickness 
reduction was 14 μm. The largest decline in thickness was 
observed in the nasal inner ring (15 μm). A difference in 
thickness change was not detected between nasal and 
temporal outer or inner rings (p = 0.50; p = 0.11, respec-
tively) or superior and inferior outer and inner rings 
(p =  0.60; p =  0.65, respectively). In the Early patients, 
E3 developed thinning at 50 months compared to base-
line, but had no follow-up visits in between. Therefore, 
it is uncertain at what time point the thinning occurred. 
Patient E5 showed thinning for the first 18 months after 
drug cessation but then the thickness increased between 
months 18 and 42.
Discussion
By using masked, trained SD-OCT graders from the 
Boston Image Reading Center (BIRC), we determined 
that structural retinal changes were common after HCQ 
cessation, occurring in 73  % of all eyes included in this 
Fig. 5 Examples of changes in SD-OCT appearance from the time of diagnosis of HCQ retinopathy (left column) to after drug cessation (right 
column). E1, left eye, shows progressive interdigitation zone disruption (arrow). E4, right eye, shows development of parafoveal EZ disruption (arrow). 
O4, right eye, shows progressive RPE atrophy of the temporal parafovea (arrow) and progressive EZ disruption of the nasal parafovea (arrowhead). 
O4, left eye, shows progressive disruption of the ELM, EZ, and RPE in the temporal parafovea (arrow). S1, left eye, shows progressive loss of the foveal 
ELM (arrow), foveal RPE migration into outer retina, and disruption with shortening of foveal RPE (ruler)
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study at a mean follow up of 26 months. All changes were 
consistent with progression of toxicity and may continue 
beyond 1 year most commonly as thinning of the parafo-
veal RPE (Fig. 6). In the Early group, 75 % had evidence 
of structural progression after drug cessation, including 
disruption of the parafoveal EZ and RPE and thinning 
of the ONL (Table  1). These eyes developed structural 
progression despite presenting with subtle changes on 
SD-OCT at the time of HCQ cessation. Three of the five 
Early patients developed worsening visual field defects in 
Fig. 6 SD-OCT changes 4 years after HCQ cessation. O6, right eye, shows development of parafoveal RPE atrophy that becomes evident 2 years 
after drug cessation and progresses at 4 year follow up. O7, left eye, shows progressive parafoveal RPE atrophy (arrow) with broadening of RPE 
migration into outer retina in the nasal parafovea (ruler)
Fig. 7 Median change in thickness in each ETDRS subfield at 12 months after HCQ cessation
Table 3 P values for  the comparison of  ETDRS subfield 
thickness changes for Obvious group
Italic value indicates significance of p value (p < 0.05)
CI 95 % confidence interval in micrometers
Early Obvious Severe
Nasal versus temporal inner 1.000 0.018
CI = − 8 to −1
0.660
Superior versus inferior inner 0.756 0.226 0.658
Nasal versus temporal outer 1.000 0.285 0.155
Superior versus inferior outer 0.626 0.291 0.264
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conjunction with structural changes. Importantly how-
ever, visual acuity and symptoms in these patients did not 
change significantly.
The disruption of the parafoveal ellipsoid zone is well-
reported in HCQ toxicity, and clinicians commonly look 
for this finding in clinical practice [4, 11–13]. In this 
report, we describe three additional, clinically useful early 
SD-OCT signs of HCQ retinal toxicity that may precede 
disruption of the parafoveal ellipsoid zone (Fig. 3). We rec-
ommend looking carefully for these early findings to assist 
in the earliest detection of retinopathy. If an abnormal-
ity is detected, the authors recommend carefully check-
ing the visual field searching for paracentral defects, as all 
Early eyes in this series had paracentral visual field defects 
at the time of drug cessation. This fact has been reported 
previously by Marmor and Melles [16] who described 
eyes with HCQ retinopathy in which the SD-OCT images 
were interpreted as normal but had paracentral visual field 
defects consistent with HCQ toxicity. Our review of these 
published images reveals that 8 of the 10 eyes displayed 
reduced reflectivity of the parafoveal EZ creating the 
appearance of a prominent foveal EZ band, suggesting that 
those eyes may have had reduced reflectivity of the para-
foveal ellipsoid zone, as found in many of the Early eyes in 
our study. A criticism of this finding that we recognize is 
that the finding may be too subtle to be assuredly detect-
able in clinical practice. Often a ‘normal’ SD-OCT can 
have variance in scan brightness affecting EZ reflectivity. 
However, in these cases, the entire EZ band, including the 
foveal and parafoveal EZ, should have homogenous or near 
homogenous reflectivity. In our study, the masked graders 
were agreeable to the interpretation of EZ reflectivity, and 
therefore, we believe the reduced reflectivity of the parafo-
veal EZ is a real detectable SD-OCT finding in early HCQ 
Fig. 8 Subanalysis for eyes with at least 3 years of follow-up after drug cessation (E3, E5, O2, O3 OD, O4, O7). (Top left) Subfoveal thickness change 
after drug cessation. (Bottom left) Example of nasal inner ring ETDRS subfield thickness change after drug cessation. (Bottom right) Mean change 
(Median change) in thickness in each ETDRS subfield
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toxicity. This sole finding should not be diagnostic of toxic-
ity, but rather used to raise suspicion for toxicity and gen-
erate further investigation.
Disruption of the parafoveal interdigitation zone (IZ) 
was another common finding (88  %) preceding parafo-
veal EZ disruption. The interdigitation zone, also known 
as the cone outer segment tip (COST) line, is the bright 
reflective line located between the EZ and the retinal 
pigment epithelium and is visible as a continuous line 
in 95  % of normal subjects [17]. This finding has been 
reported in HCQ retinopathy two times previously, and 
appears to be another important but early finding in 
Early HCQ toxicity [18, 19].
Macular thickness changes in the Early and Severe 
groups were minimal at 12  months after drug cessation. 
Changes in the Severe group were presumed secondary to 
glial and RPE remodeling as these eyes had severe para-
foveal and foveal outer retinal atrophy at the time of drug 
cessation. Obvious eyes had foveal thinning at 12 months 
similar to a previous report [11], and the macular thinning 
was not equal between the subfields. Greater thinning was 
detected in the nasal inner ring when compared to the 
temporal inner ring. This may be attributable to a thicker 
baseline nasal inner retina with more opportunity for 
thinning compared to the temporal inner retina. In addi-
tion, Obvious eyes developed greater thinning in the infe-
rior outer ring as compared to Early eyes. This suggests an 
acceleration of thinning in the inferior outer ring as toxic-
ity progresses. Interestingly, two other studies have noted 
the inferior macula may be the earliest affected quadrant 
in HCQ toxicity, but further studies are needed [18, 20]. 
Finally, this study included myopic eyes up to −6D. The 
relationship between axial length and macular thick-
ness measurements needs to be further clarified because 
axial length has both been negatively correlated to macu-
lar thickness but also not observed [21, 22]. Therefore, it 
remains unclear whether macular thickness changes in 
myopic eyes are different from emmetropic eyes.
Retained HCQ in the RPE cell may be the underlying 
cause of progressive retinal thinning observed in Obvious 
eyes after 12  months drug cessation. After intravenous 
injection of chloroquine into a rabbit, high concentra-
tions of chloroquine are found in the pigmented ocular 
tissues (RPE, choroid, iris) [23]. These levels remain high 
for over 2  months following a single administration of 
chloroquine. Albino rabbits, on the other hand, do not 
retain chloroquine in the uvea or RPE indicating that 
melanin pigment is responsible for the binding and trap-
ping of chloroquine within the cell. Once inside the RPE 
cell, HCQ disrupts lysosomal function leading to lipofus-
cin accumulation and photoreceptor degeneration [24]. 
We suspect HCQ is retained in the RPE cell for a pro-
longed period of time after drug cessation and may lead 
to progressive RPE atrophy, retinal thinning, and worsen-
ing visual field defects as observed in this study.
We did not observe improvement in visual acuity or 
visual fields after drug cessation. However, a study by 
Mititelu et  al. [25] reported two patients with improve-
ment in visual acuity and visual fields after HCQ ces-
sation. The authors also observed parafoveal EZ 
regeneration and suggested the presence of an intact 
ELM at the time of drug cessation as a positive predictor 
for EZ regeneration. In contrast, EZ regeneration was not 
observed in our study, but progressive EZ disruption was 
noted in over half. Further studies are needed to support 
these findings.
SD-OCT, in combination with Humphrey’s visual field 
10-2, as well as fundus autofluorescence and multifocal 
ERG in select patients, is critical for the early detection of 
HCQ retinopathy. As shown by this study and by Marmor 
and Melles [16], cases of early HCQ toxicity that display 
visual field changes attributable to HCQ toxicity in the set-
ting of a ‘normal SD-OCT’ may in fact have early changes 
on SD-OCT as described in this report. We did not, how-
ever, observe any cases of HCQ retinopathy in which the 
visual field was normal but where morphological SD-OCT 
changes were detected. Therefore, a reliable visual field 
may be the most sensitive test for detecting early toxic-
ity. However, fields are often unreliable, and SD-OCT 
has value in assisting detection in these cases. SD-OCT 
can also be used to corroborate early visual field defects. 
Conversely, if a parafoveal field defect is detected, we rec-
ommend repeating the field before deeming the finding 
unreliable.
Conclusions
SD-OCT can show signs of early HCQ retinopathy 
before unmistakable parafoveal EZ disruption develops, 
and these signs may assist in earlier detection of HCQ 
toxicity. Early detection is critical because both structural 
and functional progression may occur after the drug is 
discontinued.
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